2019-08-19 NO.50 | More News | Home | CMU
 
Mien-Chie Hung,President
Chung Y. Hsu,Chief Consultant

Major Breakthrough for Immunotherapy of Cancers - A China Medical University Research Team Led by President Mien-Chi Hung Has Published It’s Research Results in 《Journal of Clinical Investigation》, An Internationally Renowned Journal.

Another breakthrough advance in immunotherapy of cancers has been made in Taiwan. The research team led by President Mien-Chi Hung of China Medical University, an internationally renowned scientist on cancer genetics, in collaboration with a sister institution, University of Texas MD Anderson Cancer Center, has discovered that combination of IL-6 antibody and an anti-T-cell immunoglobulin (Tim-3) has overcome the resistance of cancer cells to therapy with checkpoint inhibitors, leading to enhanced efficacy of immunotherapy. This finding has raised exciting prospect in the field for making greater impact and covering a broader scope to benefit a greater population of cancer patients.


To Strengthen Precision in Target Therapy of Cancers - An International Research Team Led by President Mien-Chi Hung at China Medical University Has Published Important Results in An Internationally Renowned Journal 《Cancers Cell》

A breakthrough has been made in uncovering the mystery of the failure for detecting PD-L1!  An international research team led by President Mien-Chi Hung at China Medical University has developed a novel strategy by applying specific enzymes to delete modified glycosylation in cellular PDL-1 to remove it’s masking for PDL-1 to be more easily recognized by the anti-PDL-1 antibody. More specifically, removal of N-linked glycosylation facilitate PDL-1 detection to enhance the therapeutic efficacy of anti-PD-1/anti-PDL-1. Experimental results based on this breakthrough strategy were published in an internationally renowned journal Cancers Cellon July 19, 2019.  Based on this innovative approach, target therapy for cancers has been made more precise for applications in a broader scope of patients with different cancer types to derive greater benefit from immunotherapy.  

Note: The title of this Cancer Cell paper is : 『Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy』


“Low Sugar” Protects Your Pancreas - A Research Team Led by Academician Wen-Hwa Lee, A Chair Professor at China Medical University, Has Made A New Discovery That The Critical Mechanism Leading to The Development of Pancreatic Cancer Is Metabolic Derangeme

“Sugar” is a risk factor for damaging pancreas! Academician Wen-Hwa Lee at Academia Sinica and a China Medical University research team have made another new discovery on 「the causal link」of metabolic derangement to the pathogenesis of pancreatic cancer. Avoiding intake of「high content of sugar」 can protect the pancreas against injury caused by metabolic derangement to lower the risk of developing pancreatic cancer. This landmark research accomplishment on a serious disease was published on March 7, 2019 in an internationally renowned journal, Cell Metabolism. 


Cell Therapy - Leading the Trend ~ China Medical University Hospital Opened 「Cell Therapy Center」

China Medical University Hospital 「Cell Therapy center」was installed on June 18 and has launched Phase IV enrollment and therapy of 8 types of cancers. Chairman Chang-Hai Tsai of the Board of Trustees, China Medical University and Healthcare System stated in the opening ceremony that this research team at China Medical University Hospital has devoted to the pioneering topnotch research on cell therapy for more than 10 years and has been endlessly searching for innovative breakthroughs to establish the therapeutic efficacy of cell therapy under approval and with special regulatory rules established by the Ministry of Health and Welfare. It is a promising hope for patients in need of cell therapy. 


A New Cancer Research Horizon - President Mien-Chie Hung at China Medical University was invited by American Association for Cancer Research (AACR) to attend the 5th AACR International Conference and Deliver a Lecture

American Association for Cancer Research (AACR) held its 5th international conference to broaden the novel view on cancer research and invited President Mien-Chi Hung of China Medical University to deliver a lecture entitled: “Marker-guided target therapy, PARP inhibitors, and development of effective immune checkpoint therapy” for sharing the recent advances of cancer research in Taiwan. President Hung also exchanged views with internationally renowned cancer investigators to explore opportunities for collaboration to raise the visibility of Taiwan in advancing cancer research on this international platform of academic research.


World-Class Topnotch Scientific Expertise - President Mien-Chi Hung of China Medical University was invited to Harvard University to Deliver a Lecture to Raise the International Visibility of Taiwan

The research team at China Medical University under the guidance of President Mien-Chi Hung, aiming to become a world-class cancer research center, has brilliant research accomplishments.  After attending the 2019 American Association of Cancer Research Annual Conference, President Hung was invited to Harvard University to deliver a lecture entitled “Marker-Guided Target Therapy, PAPR and EGFR Inhibitors and Development of Effective Immune Checkpoint Therapy” to share research experiences with internationally renowned experts in advancing biomedical research accomplishments in Taiwan to the academic stage in the world for raising the international visibility of Taiwan.


Achievements Made in Cancer Research Brighten Taiwan ~ President Mien-Chi Hung of China Medical University was Invited by The American Association of Cancer Research (AACR) to Attend the AACR Annual Conference and to Deliver a Lecture Entitled「The Critica

President Mien-Chi Hung of China Medical University is a world-renowned expert on molecular biology and genetic mechanisms of carcinogenesis. He was invited to attend the 2019 AACR Annual Meeting held at University of Atlanta on March 29, 2019 to deliver a lecture on a cancer research topic of broad interest. President Hung presented the latest research accomplishments in a lecture entitled「The Critical Role of PD-L1 Glycolslation」and received praises from world-class scientists who attended this conference to appreciate the accelerated advances in cancer research in Taiwan.


New Discovery for Prevention and Treatment of Delirium ~Prof. Kuan-Pin Su at China Medical University Brought Together Researchers across Nations to Publish Research Accomplishments in an Internationally Renowned Journal, JAMA Psychiatry

It’s a great news for patients with delirium! Under the leadership of Prof. Kuan-Pin Su. A Research team with collaborators across nations has made new discovery. Remolten, a melatonin agonist, has profound effect in preventing delirium in patients with this serious psychiatric disorder.  This research finding, published on February 27, 2019 in an internationally renowned journal, JAMA Psychiatry, is helpful for clinicians to have a new research as well as therapeutic option beyond the currently available choices of drug therapy for delirium.


Ministry of Science and Technology Joins China Medical University in Promoting 「Topnotch Biotechnology and Healthcare International Consortium」or Global Research and Industry Alliance (GLORIA) to Advance International Industrial Competitiveness

In order to establish the industrial assets based on industry-academy collaboration, Ministry of Science and Technology has selected China Medical University to be one of the universities in a joint promotion of 「Topnotch Biotechnology International Consortium」or Global Research and Industry Alliance (GLORIA) to build internationally competitive force in topnotch biotech healthcare、minimally invasive medical devices、artificial intelligence therapeutic instruments and novel health block chain industrial cluster in central Taiwan region. Biotech companies are welcome to join this Global Research and Industry Alliance (GLORIA) for promoting industrial competitiveness in the world.


Starting a New Era of AI Healthcare in Taiwan – China Medical University Signed Contract with Everfortune.AI CO.,LTD for Technology Transfer of AI Applications

China Medical University, in collaboration with Ministry of Science and Technology, has jointly advanced「Topnotch Biotechnology International Consortium」or Global Research and Industry Alliance (GLORIA) and has generated fruitful achievements in the new field of AI healthcare. On May 24, under the oversight of Deputy Director General Chun-yi Tu, Department of Academia-Industry Collaboration and Science Park Affairs, Ministry of Science and Technology, Vice President Hung-Che Chiang, representing China Medical University, signed AI application technology transfer with Everfortune.AI CO.,LTD to start a new era in the development of AI-based healthcare services.


Application of Artificial Intelligence (AI) in Research on New Drug Exploration – China Medical University and National Singapore University Convened the 2019 Bilateral Research Conference

With the arrival of a new era on AI, President Mien-Chi Hung of China Medical University attended a joint research conference co-sponsored by National Singapore University and encouraged scholars in both universities to capture the new technical trend in applying big data and AI in new drug R&D with promising perspective for shortening the time course and raising the successful rate.

 

 


International Bilateral Collaboration on Cancer Research – China Medical University and Healthcare System Signed Memorandum of Agreement for Collaboration with National Singapore University Healthcare System

Deputy Chief Executive Khay Guan YEOH of The Healthcare System at National Singapore University was invited to visit China Medical University for academic exchange for 2 days and delivered 2 lectures entitled “New Methods for the Early Detection of Gastric Cancer” and ”How Do We Detect Early Gastric Cancer? Results from an Endoscopic Surveillance Programme (GCEP) ” respectively. Deputy Chief Executive YEOH also signed memorandum of agreement for close collaboration with China Medical University and Healthcare System in teaching, research, healthcare and clinical trials.


Make A Great Dream to Enjoy Scientific Pleasure – China Medical University Received The Ministry of Science and Technology Shackleton Program Grant to Lead the Research Team in Breaking the Toughest Constraint of Science

In order to promote academic leaders, the Ministry of Science and Technology (MOST) offered the MOST Shackleton Program Grant. The research team on cancer biology at China Medical University has received this grant based on its outstanding achievements in this field. The principal investigator of this project is Academician Lu-Hai Wang, Vice President, China Medical University, who expressed strong confidence in advancing the career development of 3 promising junior investigators to strengthen their research accomplishments for becoming global leaders in cancer biology research.


Talent Leads Talent – China Medical University Has Recruited Professor Moncef Zouali, a Yushan Scholar to Enrich Academic and Research Productivity

Prof. Moncef Zouali, a citizen of France, is an immunologist with world renowned reputation in studying therapy of lupus erythematosus. Under the strategy developed at China Medical University to recruit international talents, Prof. Zouali accepted the recommendation with pleasure to travel across continents to join the topnotch team on education and research here. It will be of landmark significance for enriching academic research capacity in Taiwan and for elevating its international stature on higher education.


The Great force Generated by Team Works – President Mien-Chi Hung of China Medical University Gave A Lecture Entitled “New Drugs and Old Drugs Are All Drugs – Large and Small Molecules Could All Be Drugs”

College of Pharmacy, China Medical University held a〔Special Lecture〕and invited President Mien-Chi Hung to deliver a lecture entitled 「New Drugs and Old Drugs Are All Drugs – Large and Small Molecules Could All Be Drugs」in English, to inspired the sense of mission for faculty members and graduate students in the School of Pharmacy in drug development. Through expertise and research capability in pharmaceutical research and collaboration, it is highly likely to have the opportunity in developing drugs for advancing healthcare development!


China Medical University, in collaboration with Taiwan Instrument Research Institute, Held An Exposition on 「Medical Materials Accelerator Service Platform and Imaging Detection Instrument Demonstration」

China Medical University, in collaboration with Taiwan Instrument Research Institute, Held An Exposition on 「Medical Materials Accelerator Service Platform and Imaging Detection Instrument Display」on domestic development of biomedical microimaging and spectrum analysis systems with novel imaging detection and optical instruments to be the focus on this exhibition. Vice President Che-Hung Chiang stated in his opening remarks to expect that the innovative medical devices and biomedical service platform will facilitate the quality and speed of medical diagnosis with lower costs to benefit patients and initiate fresh research drive in biotech and healthcare industry.


A Small Giant in Biotech and Health Industry in Taiwan – China Medical University and Healthcare System and Collaborating Companies in Academia-Industry Collaboration Program Joined the Bio Asia - Taiwan Expo

2910 Bio Asia was held in Taipei Nangang Exhibition Center starting July 25 for 4 days.  China Medical University Office of Academia-Industry Cooperation joined 6 collaborating companies in this Expo.  China Medical University Hospital set 2 large exhibition sites on 「AI-based Inpatient Ward System」 and 「AI Center」respectively to display innovative development in healthcare. Chairman Chang-Hai Tsai of the China Medical University Board of Trustees, accompanied by the University Vice President Hung-Che Chiang inspected the exhibition sites to cheer the participating companies and colleagues.


Office of Academia-Industry Cooperation,
China Medical University, Taiwan
TEL: +886-4-22053366 EXT.1580, 1581, 1582
E-mail: adm29@mail.cmu.edu.tw